Takeda Provides Update on TAK-994 Clinical Program

OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a safety signal has emerged in

Read more